News

News

CTTQ of Sino Biopharm Was Awarded "Excellent" in National Enterprise Technology Center Evaluation

Release time:2022-02-24

Recently, the National Development and Reform Commission released the "Evaluation Results of National Enterprise Technology Center 2021", and the National Enterprise Technology Center of CTTQ Pharmaceutical Group was awarded"Excellent" among the 1,744 National Enterprise Technology Centers participating in the evaluation nationwide, becoming the only National Enterprise Technology Center of the pharmaceutical industry in Jiangsu Province and ranking third among pharmaceutical enterprises nationwide.

 

 

"National Enterprise Technology Center" is the highest level of China's enterprise technology center evaluation level, is an important part of the national technology innovation system, assessed and identified by the National Development and Reform Commission, Ministry of Science and Technology, Ministry of Finance, General Administration of Customs, the General Administration of Taxation. The relevant national ministries and commissions assess and evaluate innovative talents, technology accumulation, technology output, innovation benefits, etc. The evaluation results are divided into four levels: excellent, good, basically qualified and unqualified. In the evaluation of national enterprise technology centers in 2021, 72 of the 1,744 participating enterprise technology centers nationwide achieved a comprehensive evaluation of 90 points or more and were rated "excellent".

 

Since being recognized as a national enterprise technology center in 2012, CTTQ has adhered to the concept of innovation-driven development, continued to increase investment in R&D, improved the R&D innovation system, taken the unmet clinical needs as the direction of innovation, and changed from "combination of creation and imitation" to "innovation-led", and its independent innovation capability has been enhanced continuously. At present, the company has 192 projects under research, including 108 innovative drugs, has undertaken more than 30 national major special projects, has applied for more than 2,100 invention patents and has more than 700 authorized patents, forming a benign pattern of "one generation on the market, one generation in reserve and one generation in R&D".

 

CTTQ will further take advantage of the National Enterprise Technology Center, continue to increase investment in research and development, strengthen key core technologies, closely focus on the strategy of "comprehensive innovation", innovate and upgrade in the six dimensions of "science and technology, research and development, organization, mechanism, management and business", continuously drive the healthy and sustainable development of the enterprise, and make greater contributions to the cause of people's health.

 

Share: